Poseida Therapeutics Inc., a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral treatments for patients with cancer, autoimmune and rare diseases, has entered into a merger agreement to be acquired by Roche Holdings Inc. in a transaction that values the company’s total equity at approximately $1.5 billion.   The proposed acquisition aims to establish a new core capability for Roche in allogeneic cell therapy, with lead opportunities focused ...